Human clinical trial of DNA-MVA HIV vaccine candidate begins
Tuesday, September 28, 2010 - 12:35
in Health & Medicine
A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.